S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
NVCT · Nuvectis Pharma, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Nuvectis Pharma Inc (NVCT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$20.74
-0.02
(-0.07%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$20.74
$20.64
$21.69
52-WEEK RANGE
$20.74
$5.55
$29.27
What's happening
- NVCT is down 0.07% today, trading at $20.74. — Live quote
- Volume today (9,552) is well below its 3-month average of 297,260. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.30 actual vs. $-0.27 estimated (-12.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 2
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NVCT
+172.72%
vs S&P 500
+159.94%
1-YEAR RETURN
NVCT
+232.10%
vs S&P 500
+217.54%
6-MONTH RETURN
NVCT
+146.59%
3-MONTH RETURN
NVCT
+7.91%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.30
Est. $-0.27
MISS -12.3%
2026-04-26 (Q1 2026)
$-0.26
Est. $-0.32
BEAT +17.8%
2026-01-26 (Q4 2025)
$-0.31
Est. $-0.30
MISS -2.1%
2025-10-26 (Q3 2025)
$-0.33
Est. $-0.25
MISS -30.7%
Valuation Measures & Ratios
Enterprise Value4$653.6M
Forward P/E5—
PEG Ratio6-1.19
Price / Sales (TTM1)—
Price / Book763.84
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-169.47%
Return on Assets (ROA9)-96.80%
Avg Volume (3M)297,260
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $428.0M | $179.6M | $101.4M | $158.8M | $192.7M |
| P/E | -15.93 | -7.13 | -4.36 | -7.84 | -10.66 |
| Price/Book | 47.12 | 12.63 | 4.22 | 9.41 | 9.20 |
| ROE | -295.82% | -177.06% | -96.96% | -120.00% | -86.30% |
| ROA | -120.07% | -99.13% | -65.42% | -74.97% | -59.98% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short2,522,106
Change from Prior Settlement+6.75%
% of Float—
Days to Cover (Short Ratio)10.34
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +232.1%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-08-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NVCT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$7.2M | -$6.3M | -$7.8M | -$6.6M | -$5.6M | -$4.4M | -$4.6M | -$4.4M |
| Net income | -$7.0M | -$6.0M | -$7.5M | -$6.3M | -$5.3M | -$4.2M | -$4.4M | -$4.2M |
| EPS (diluted) | $-0.30 | $-0.26 | $-0.44 | $-0.30 | $-0.27 | $-0.24 | $-0.26 | $-0.25 |
| EPS (basic) | $-0.30 | $-0.26 | $-0.44 | $-0.30 | $-0.27 | $-0.24 | $-0.26 | $-0.25 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $22.4M | $25.4M | $31.7M | $35.6M | $27.0M | $30.1M | $18.6M | $17.3M |
| Total liabilities | $13.3M | $11.2M | $13.3M | $11.6M | $10.1M | $9.2M | $8.9M | $6.3M |
| Stockholders' equity | $9.1M | $14.2M | $18.4M | $24.0M | $16.9M | $21.0M | $9.7M | $11.0M |
| Total current assets | $22.4M | $25.4M | $31.7M | $35.6M | $27.0M | $30.1M | $18.6M | $17.3M |
| Total current liabilities | $13.3M | $11.2M | $13.3M | $11.6M | $10.1M | $9.2M | $8.9M | $6.3M |
| Cash & equivalents | $22.2M | $25.1M | $31.6M | $35.4M | $26.8M | $29.9M | $18.5M | $17.2M |
| Other current assets | $216.0K | $268.0K | $75.0K | $145.0K | $214.0K | $284.0K | $74.0K | $138.0K |
| Accounts payable | $5.2M | $4.7M | $6.3M | $6.4M | $5.0M | $3.0M | $2.5M | $2.3M |
| Accrued liabilities | $92.0K | $36.0K | $115.0K | $65.0K | $2.0K | $865.0K | $840.0K | $282.0K |
| Retained earnings | -$112.8M | -$105.7M | -$99.7M | -$92.4M | -$84.9M | -$78.6M | -$73.2M | -$67.0M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.5M | -$6.5M | -$4.0M | -$4.5M | -$3.4M | -$4.2M | -$2.5M | -$2.4M |
| Investing cash flow | — | $0 | — | — | — | $0 | $0 | — |
| Financing cash flow | $1.6M | $7.0K | $166.0K | $13.1M | $296.0K | $15.5M | $3.8M | $1.5M |
| Share-based compensation | $1.7M | $1.9M | $1.5M | $1.5M | $1.7M | $1.4M | $1.1M | $1.2M |
| Change in accounts payable | $489.0K | -$1.6M | -$165.0K | $1.5M | $2.0M | $494.0K | $237.0K | $415.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$27.6M | -$19.8M | -$22.9M | -$19.2M | -$12.9M |
| Net income | -$26.4M | -$19.0M | -$22.3M | -$19.1M | -$12.9M |
| EPS (diluted) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
| EPS (basic) | $-1.32 | $-1.11 | $-1.43 | $-1.51 | $-3.02 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $31.7M | $18.6M | $19.2M | $20.4M | $6.7M |
| Total liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Stockholders' equity | $18.4M | $9.7M | $12.2M | $14.2M | -$11.0M |
| Total current assets | $31.7M | $18.6M | $19.2M | $20.4M | $5.8M |
| Total current liabilities | $13.3M | $8.9M | $7.0M | $6.2M | $2.4M |
| Cash & equivalents | $31.6M | $18.5M | $19.1M | $20.0M | $5.7M |
| Other current assets | $75.0K | $74.0K | $59.0K | $412.0K | $91.0K |
| Accounts payable | $6.3M | $2.5M | $2.8M | $2.9M | $1.1M |
| Accrued liabilities | $115.0K | $840.0K | $415.0K | $445.0K | $395.0K |
| Retained earnings | -$99.7M | -$73.2M | -$54.2M | -$32.0M | -$12.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$16.0M | -$12.2M | -$16.0M | -$13.6M | -$9.5M |
| Investing cash flow | — | $0 | $0 | $0 | — |
| Financing cash flow | $29.1M | $11.7M | $15.1M | $27.8M | $15.2M |
| Share-based compensation | $6.0M | $4.9M | $4.7M | $1.7M | $1.9M |
| Change in accounts payable | $3.8M | -$273.0K | -$139.0K | $1.9M | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NVCT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-01-02 to 2026-08-03
Recent transactions
- Insiders have net bought 62,500 shares over the last 182 days, across 2 purchases and 0 sales.
- Most recent: Carson Michael J. (Vice President, Finance) — Grant / award of 30,000 shares on 2026-08-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)62,500 sh(2 txns)
Sales (open market)0 sh(0 txns)
Net Shares+62,500
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Carson Michael J. | Vice President, Finance | Grant / award | 2026-08-03 | 30,000 |
| Mosseri Marlio Charles | 10% owner | Open market purchase | 2026-06-30 | 50,000 |
| BENTSUR RON | Chairman & CEO | Open market purchase | 2026-06-30 | 12,500 |
| Hoberman Kenneth | Director | Grant / award | 2026-06-11 | 35,000 |
| Oliviero James F III | Director | Grant / award | 2026-06-11 | 35,000 |
| Sanchez Juan | Director | Grant / award | 2026-06-11 | 35,000 |
| Kaplan Matthew L. | Director | Grant / award | 2026-06-11 | 35,000 |
| Shemesh Shay | Chief Dev. & Ops. Officer | Grant / award | 2026-01-06 | 150,000 |
| Poradosu Enrique | Chief Science & Business Off | Grant / award | 2026-01-06 | 150,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-03 | Carson Michael J. | Vice President, Finance | Grant / award | 30,000 | $0.00 |
| 2026-06-30 | Mosseri Marlio Charles | 10% owner | Open market purchase | 50,000 | $18.32 |
| 2026-06-30 | BENTSUR RON | Chairman & CEO | Open market purchase | 12,500 | $20.00 |
| 2026-06-11 | Hoberman Kenneth | Director | Grant / award | 35,000 | $0.00 |
| 2026-06-11 | Oliviero James F III | Director | Grant / award | 35,000 | $0.00 |
| 2026-06-11 | Sanchez Juan | Director | Grant / award | 35,000 | $0.00 |
| 2026-06-11 | Kaplan Matthew L. | Director | Grant / award | 35,000 | $0.00 |
| 2026-01-06 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant / award | 150,000 | $0.00 |
| 2026-01-06 | BENTSUR RON | Chairman & CEO | Grant / award | 150,000 | $0.00 |
| 2026-01-06 | Poradosu Enrique | Chief Science & Business Off | Grant / award | 150,000 | $0.00 |
| 2026-01-06 | Carson Michael J. | Vice President, Finance | Grant / award | 61,200 | $0.00 |
| 2025-11-05 | BENTSUR RON | Chairman & CEO | Open market purchase | 5,000 | $5.72 |
| 2025-11-05 | Sanchez Juan | Director | Open market purchase | 13,000 | $5.79 |
| 2025-11-05 | Kaplan Matthew L. | Director | Open market purchase | 11,000 | $5.84 |
| 2025-10-27 | Mosseri Marlio Charles | 10% owner | Open market purchase | 72,836 | $6.28 |
| 2025-10-24 | Mosseri Marlio Charles | 10% owner | Open market purchase | 35,034 | $6.15 |
| 2025-10-23 | Mosseri Marlio Charles | 10% owner | Open market purchase | 46,900 | $6.06 |
| 2025-09-22 | Sanchez Juan | Director | Grant / award | 30,000 | $0.00 |
| 2025-06-20 | Mosseri Marlio Charles | 10% owner | Open market purchase | 5,603 | $7.99 |
| 2025-06-18 | Mosseri Marlio Charles | 10% owner | Open market purchase | 28,043 | $8.05 |
| 2025-06-17 | Mosseri Marlio Charles | 10% owner | Open market purchase | 5,399 | $8.11 |
| 2025-06-12 | Kaplan Matthew L. | Director | Grant / award | 30,000 | $0.00 |
| 2025-06-12 | Oliviero James F III | Director | Grant / award | 30,000 | $0.00 |
| 2025-06-12 | Hoberman Kenneth | Director | Grant / award | 30,000 | $0.00 |
| 2025-05-12 | Mosseri Marlio Charles | 10% owner | Open market purchase | 21,167 | $8.11 |
| 2025-05-08 | Mosseri Marlio Charles | 10% owner | Open market purchase | 50 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | 10% owner | Open market purchase | 100 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | 10% owner | Open market purchase | 100 | $8.65 |
| 2025-05-08 | Mosseri Marlio Charles | 10% owner | Open market purchase | 2,400 | $8.65 |
| 2025-05-07 | Mosseri Marlio Charles | 10% owner | Open market purchase | 2,703 | $8.40 |
| 2025-05-07 | Mosseri Marlio Charles | 10% owner | Open market purchase | 9,614 | $8.64 |
| 2025-05-06 | Mosseri Marlio Charles | 10% owner | Open market purchase | 2,340 | $8.40 |
| 2025-05-06 | Mosseri Marlio Charles | 10% owner | Open market purchase | 10,104 | $8.64 |
| 2025-02-07 | Mosseri Marlio Charles | 10% owner | Open market purchase | 240,000 | $5.00 |
| 2025-01-02 | Shemesh Shay | Chief Dev. & Ops. Officer | Grant / award | 150,000 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:21 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-21 | 8-K | 2026-07-20 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-30 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-29 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-23 | 8-K | 2026-06-22 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about NVCT (Nuvectis Pharma, Inc.). Links open the publisher — we don’t host full articles.
-
BABA,AMAT,FIVE,ATLC,PBF,PRM,SHPH,PSNY,NVCT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
AIRG,EML,DOMH,ATLO,HGBL,SLND,SLRC,FBK,HASI,VANI,SFST,ASYS,ASLE,RMCF,CMTL,NVCT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-20 -
Insider Purchase: 10% owner at $NVCT Buys 50,000 Shares
Quiver Quantitative · 2026-10-19 -
SFST,ASYS,AIRG,ASLE,BSBK,DOMH,FSCO,RMCF,NVCT,CMTL,FBK,HASI | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-19 -
NVCT Jan 2027 35.000 call (NVCT270115C00035000) stock price, news, quote and history
Yahoo Finance UK · 2026-10-18 -
RILY,CCNE,MCB,NEE,NEWT,BCBP,FIS,MTDR,SFST,PCF,BPRN,NKSH,BY,NMFC,TRST,GLSI,SHBI,BOTJ,NVCT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-18 -
NVCT Oct 2026 10.000 put (NVCT261016P00010000) interactive stock chart
Yahoo Finance UK · 2026-10-18 -
Understanding Momentum Shifts in (NVCT)
Stock Traders Daily · 2026-10-17
No headlines in this category right now — try “All”.